Rhythm Pharmaceuticals

$31.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.92 (-8.58%) Today

$0.00 (0.00%) As of 11:40 AM UTC after-hours

Why Robinhood?

You can buy or sell RYTM and other stocks, options, and ETFs commission-free!

About RYTM

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. The listed name for RYTM is Rhythm Pharmaceuticals, Inc. Common Stock.

CEO

David P. Meeker

Employees

Headquarters

Boston, Massachusetts

Founded

2010

Market Cap

1.58B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

585.51K

High Today

$34.05

Low Today

$30.35

Open Price

$34.05

Volume

1.01M

52 Week High

$43.26

52 Week Low

$12.99

Collections

Analyst Ratings

75%

of 8 ratings

Buy

75%

Hold

13%

Sell

13%

RYTM Earnings

-$1.24

-$0.83

-$0.41

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 1, Pre-Market